Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
April 10, 2006
- BUSINESS NEWS IN BRIEF
April 10, 2006
- JMA
April 10, 2006
- FY2006 Budget Proposal Approved
April 10, 2006
- 39 of World's 99 Top-Selling Drugs Unapproved in Japan: Mr Wolf of PhRMA
April 10, 2006
- Korosho to Gear Up Steps to Eliminate Provisional Delivery
April 10, 2006
- Economist Conferences: 5th Roundtable on Healthcare Reform in Japan
April 10, 2006
- REGULATORY NEWS IN BRIEF
April 10, 2006
- Daiichi Sankyo Selects 5 Top-Priority Projects
April 10, 2006
- Ono, Medarex in Collaboration to Develop Antibody Therapeutics
April 10, 2006
- R&D NEWS IN BRIEF
April 10, 2006
- TeGenero's Investigational Antibody Drug Causes Disaster in PI Trial
April 3, 2006
- The WHO, IFPMA to Cooperate to Combat Counterfeit Drugs
April 3, 2006
- Korosho to Standardize Package Inserts for Generics
April 3, 2006
- REGULATORY NEWS IN BRIEF
April 3, 2006
- Shift to Low-priced Drugs Could Weaken Wholesalers: FJPWA
April 3, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 3, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 3, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 3, 2006
- STATISTICS
April 3, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…